Institutional members access full text with Ovid®

Share this article on:

Clinical Evaluation of Vancomycin Dosage in Pediatric Oncology Patients

Sanders, Stefan J.W.J. PharmD*; Bijleveld, Yuma A. PharmD*; Sinkeler, Fleur BSc*; Kemper, Elles M. PharmD, PhD*; Pajkrt, Dasja MD, PhD, MBA; van de Wetering, Marianne MD, PhD; van Eijkelenburg, Natasha K.A. MD; Mathôt, Ron A.A. PharmD, PhD*

The Pediatric Infectious Disease Journal: July 2014 - Volume 33 - Issue 7 - p 731–733
doi: 10.1097/INF.0000000000000268
Antimicrobial Reports

Vancomycin trough serum concentrations were below therapeutic range (8–15 mg/L) in 58% of 124 pediatric oncology patients receiving 60 mg/kg/d divided qid. Patients <6 and between 6 and 12 years had significantly lower trough concentrations than patients >12 years. A vancomycin dosage of 60 mg/kg/d is inadequate for pediatric oncology patients >12 years.

From the *Department of Clinical Pharmacy; Department of Pediatric Infectious Diseases; and Department of Pediatric Oncology, Emma Children’s Hospital, Academic Medical Center, Amsterdam, The Netherlands.

Accepted for publication December 16, 2013.

The authors have no funding or conflicts of interest to disclose.

Address for correspondence: Ron A.A. Mathôt, PharmD, PhD, Department of Clinical Pharmacy, Academic Medical Center, PO Box 22660, 1100 DD, Amsterdam, The Netherlands. E-mail: r.mathot@amc.uva.nl.

© 2014 by Lippincott Williams & Wilkins, Inc.